Jonathan Aschoff
Stock Analyst at Roth Capital
(0.54)
# 4,159
Out of 5,169 analysts
39
Total ratings
26.53%
Success rate
-34.69%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Buy | $57 → $55 | $24.08 | +128.41% | 2 | Feb 26, 2026 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.43 | +2,464.10% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.55 | +119.90% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $4.67 | +2,281,698.72% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $0.23 | +7,763.70% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.04 | +68,553.85% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $1.42 | +35,111.27% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $2.08 | +47,976.92% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $3.25 | +25,746.15% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $2.07 | +869,465.22% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $15.57 | +92.74% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $6.57 | +2,944.14% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $9.46 | +47.99% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.22 | +7,081,867.21% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $2.29 | +249.34% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.88 | +5,219.15% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.87 | +45,951.12% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $5.95 | +538.66% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.66 | +5,683.13% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.24 | +948.39% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $57 → $55
Current: $24.08
Upside: +128.41%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.43
Upside: +2,464.10%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.55
Upside: +119.90%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $4.67
Upside: +2,281,698.72%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $0.23
Upside: +7,763.70%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.04
Upside: +68,553.85%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $1.42
Upside: +35,111.27%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $2.08
Upside: +47,976.92%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $3.25
Upside: +25,746.15%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $2.07
Upside: +869,465.22%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $15.57
Upside: +92.74%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $6.57
Upside: +2,944.14%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $9.46
Upside: +47.99%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.22
Upside: +7,081,867.21%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $2.29
Upside: +249.34%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $1.88
Upside: +5,219.15%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.87
Upside: +45,951.12%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $5.95
Upside: +538.66%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.66
Upside: +5,683.13%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.24
Upside: +948.39%